can they use the results obtained in the US to file for approval abroad? Otherwise it's pointless to talk about partners etc. I think their commercial strategy is not very well communicated. There are other companies they do a much better job.
"I think their commercial strategy is not very well communicated. There are other companies they do a much better job."
I was recently in a courtroom for a case. One of the parties had major cognition issues. She complained to the judge that nobody would explain a certain aspect of the case to her, even though I had personally heard it explained to her by multiple people. The judge took a few minutes to explain things in very simple terms, and it was obvious to everyone else in the room just how much he was talking down to her. He sounded ridiculous. However, when he finished, the woman thanked him and told him he explained things much better than others.
The moral of the story is that if the company takes the time to explain everything so that the stupidest people (like you) can understand, they will sound ridiculous to the vast majority of everyone else.
I am typically quite critical of biotech IR, but I think ACAD does a very good job of explaining their plans and strategies. Maybe you should listen to the presentation from yesterday, or listen again. They don't over hype, they just presented the facts as they are today, the market opportunity, the competition and the shortcomings of the currently approved drug. If I were a senior level BD pro at LLY, FRX or another company operating in their space, I would make them an offer at 2x the current price and hope they say yes because in a late 2014 IMO the price will probably be $12-18. With additional funding and resources a large pharma could advance Pima more rapidly in Alzheimers and Schiz.
Of course they can't use study results from the United States to apply elsewhere. Science in the US does not translate overseas. I think it has something to do with the metric system. This is exactly why we're seeing the pps drop this afternoon... duh!